The magnitude of GSK's reach is evidenced by a product portfolio that spans several therapeutic classes. The diverse platform insulates the company from problems with any single product.

The four-pronged strategy begins with the acquisition of GSK's oncology portfolio, which includes all of its marketed products and late-stage candidates, for $14.5 billion, with a further $1.5 ...

The cancer portfolio also put in a buoyant ... climbed 41 per cent to £101 million. The latter product will of course not have an impact on GSK's future growth, as it is one of the oncology ...

We recently published a list of the 7 Most Undervalued Biotech Stocks To Invest In. In this article, we are going to take a ...

Pharma major GSK (LSE: GSK) on Tuesday said its urinary tract infection treatment gepotidacin, under the brand name Blujepa, ...